Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Analysts at SVB Leerink

SVB Leerink assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) in a research report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Cowen raised their price target on Regeneron Pharmaceuticals from $640.00 to $645.00 in a research report on Wednesday, April 20th. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $605.00 to $632.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. StockNews.com upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 14th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $754.00 to $728.00 and set a “buy” rating for the company in a research note on Tuesday, February 8th. Finally, Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $690.00 to $692.00 and gave the stock an “overweight” rating in a report on Friday, February 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $724.63.

Shares of NASDAQ REGN opened at $661.14 on Monday. Regeneron Pharmaceuticals has a one year low of $492.13 and a one year high of $747.42. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.76 and a quick ratio of 4.09. The business’s fifty day moving average price is $681.16 and its 200-day moving average price is $646.13. The stock has a market capitalization of $71.76 billion, a PE ratio of 9.36, a P/E/G ratio of 1.26 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.37 by $2.12. The business had revenue of $2.97 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Regeneron Pharmaceuticals had a return on equity of 50.10% and a net margin of 48.06%. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $10.09 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 40.26 EPS for the current fiscal year.

In related news, EVP Plew Daniel P. Van sold 6,781 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, February 23rd. The shares were sold at an average price of $613.99, for a total value of $4,163,466.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $701.82, for a total transaction of $701,820.00. Following the completion of the sale, the executive vice president now owns 22,014 shares of the company’s stock, valued at approximately $15,449,865.48. The disclosure for this sale can be found here. Insiders sold a total of 44,559 shares of company stock worth $30,297,368 over the last ninety days. 11.84% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. BlackRock Inc. grew its position in Regeneron Pharmaceuticals by 2.6% during the fourth quarter. BlackRock Inc. now owns 9,610,871 shares of the biopharmaceutical company’s stock worth $6,069,457,000 after buying an additional 244,009 shares during the period. Vanguard Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 8,360,330 shares of the biopharmaceutical company’s stock valued at $5,839,023,000 after buying an additional 201,815 shares during the period. Capital World Investors lifted its stake in shares of Regeneron Pharmaceuticals by 11.8% during the first quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock valued at $4,155,451,000 after buying an additional 626,199 shares during the period. State Street Corp raised its stake in Regeneron Pharmaceuticals by 6.8% during the first quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock worth $3,579,729,000 after purchasing an additional 325,645 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Regeneron Pharmaceuticals by 11.9% during the fourth quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock worth $2,899,642,000 after purchasing an additional 489,084 shares during the period. 83.83% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More